Home Companies Catalysts Deep Dives
Myrbetriq mirabegron APPROVED
Drug Profile
ModalitySmall molecule
RoutePO
Therapy AreaOther
Launch2012-06-28
US LOE2025-06-28
Peak Sales Est$2000M
Formulations[{"id":"myrbetriq-er","route":"PO","setting":"PATIENT_SELF","frequency":"Once daily","is_primary":tr
Companies
ALPMY (ORIGINATOR)100%
Mechanism: Beta-3 adrenergic agonist
Expert: Selective beta-3 adrenoceptor agonist for overactive bladder.
Everyday: Relaxes bladder muscles to reduce urinary urgency.
Targets: ["ADRB3"]
Revenue History
PeriodRevenue ($M)
FY2023$1,400M
FY2024$1,200M
Programs (1)
IndicationStageKey StudyRegional Status
Overactive bladderAPPROVEDSCORPIO/ARIES[{"stage":"APPROVED","region":"US","approval_date":"2012-06-28"}]
Notes
Overactive bladder treatment. Facing generic competition.
Data from Supabase · Updated 2026-03-24